HRMY · Harmony Biosciences Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $215.39M | - | $239.46M | $200.49M | $184.73M | - | $186.04M | $172.81M | $154.62M | - |
| Cost of Revenue | $44.51M | - | $59.65M | $38.15M | $31.99M | - | $42.78M | $32.14M | $27.48M | - |
| Gross Profit | $170.88M | - | $179.81M | $162.34M | $152.74M | - | $143.26M | $140.67M | $127.13M | - |
| R&D | $69.38M | - | $54.96M | $50.16M | $34.54M | - | $25.39M | $63.58M | $22.19M | - |
| SG&A | $32.51M | - | $29.81M | $33.92M | $31.24M | - | $28.59M | $27.22M | $25.68M | - |
| Total Operating Expenses | $133.58M | - | $114.32M | $114.16M | $96.49M | - | $81.55M | $119.31M | $75.10M | - |
| D&A | $7.0K | - | - | - | $7.0K | - | - | - | $163.0K | - |
| Operating Income | $37.29M | - | $65.49M | $48.18M | $56.24M | - | $61.71M | $21.36M | $52.03M | - |
| Interest Expense | $3.23M | - | $3.62M | $3.65M | $3.84M | - | $4.35M | $4.40M | $4.54M | - |
| Income Tax | $7.20M | - | $16.63M | $9.86M | $11.62M | - | $16.08M | $10.10M | $13.45M | - |
| Net Income | $32.49M | - | $50.87M | $39.78M | $45.56M | - | $46.09M | $11.59M | $38.33M | - |
| EPS - Basic | $0.56 | - | $0.88 | $0.69 | $0.79 | - | $0.81 | $0.20 | $0.68 | - |
| EPS - Diluted | $0.55 | - | $0.87 | $0.68 | $0.78 | - | $0.79 | $0.20 | $0.67 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $589.40M | $752.50M | $647.00M | $546.05M | $489.00M | $453.00M | $387.37M | $317.30M | $332.98M | $311.66M |
| Accounts Receivable | $108.22M | $96.79M | $100.65M | $92.98M | $105.97M | $83.03M | $81.50M | $83.16M | $79.72M | $74.14M |
| Inventory | $5.28M | $5.36M | $6.88M | $6.10M | $6.38M | $7.20M | $6.92M | $5.64M | $5.86M | $5.36M |
| Accounts Payable | $28.60M | $17.69M | $26.34M | $28.30M | $17.46M | $13.74M | $10.53M | $22.68M | $15.14M | $17.73M |
| Current Assets | $778.82M | $907.01M | $838.80M | $691.35M | $642.69M | $579.25M | $522.40M | $458.34M | $479.50M | $451.07M |
| Total Assets | $1.27B | $1.27B | $1.21B | $1.11B | $1.06B | $999.20M | $928.13M | $858.38M | $846.99M | $811.45M |
| Current Liabilities | $217.34M | $252.13M | $223.40M | $180.13M | $175.12M | $175.08M | $161.28M | $146.58M | $154.25M | $163.78M |
| Long-term Debt | $138.81M | $143.66M | $148.51M | $153.34M | $158.18M | $163.02M | $167.85M | $171.42M | $175.00M | $178.57M |
| Total Liabilities | $361.48M | $401.41M | $373.10M | $334.93M | $335.01M | $340.05M | $331.33M | $319.80M | $331.59M | $344.46M |
| Stockholders' Equity | $910.35M | $870.22M | $835.12M | $773.08M | $720.52M | $659.15M | $596.80M | $538.58M | $515.39M | $466.99M |
| Retained Earnings | $193.39M | $160.90M | $138.42M | $87.55M | $47.78M | $2.22M | ($47.26M) | ($93.35M) | ($104.94M) | ($143.28M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $27.76M | - | - | - | $33.99M | - | - | - | $31.14M | - |
| Investing Cash Flow | ($183.65M) | - | - | - | $2.36M | - | - | - | ($6.19M) | - |
| Financing Cash Flow | ($7.22M) | - | - | - | ($352.0K) | - | - | - | ($3.63M) | - |
| CapEx | - | - | - | - | $128.0K | - | - | - | $5.0K | - |
| Free Cash Flow | - | - | - | - | $33.86M | - | - | - | $31.14M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 79.3% | - | 75.1% | 81.0% | 82.7% | - | 77.0% | 81.4% | 82.2% | - |
| Operating margin | 17.3% | - | 27.3% | 24.0% | 30.4% | - | 33.2% | 12.4% | 33.7% | - |
| EBITDA margin | 17.3% | - | - | - | 30.5% | - | - | - | 33.8% | - |
| Net margin | 15.1% | - | 21.2% | 19.8% | 24.7% | - | 24.8% | 6.7% | 24.8% | - |
| Free cash flow margin | - | - | - | - | 18.3% | - | - | - | 20.1% | - |
| FCF / Net income | - | - | - | - | 0.74 | - | - | - | 0.81 | - |
| R&D / Revenue | 32.2% | - | 23.0% | 25.0% | 18.7% | - | 13.6% | 36.8% | 14.4% | - |
| SG&A / Revenue | 15.1% | - | 12.4% | 16.9% | 16.9% | - | 15.4% | 15.8% | 16.6% | - |
| Effective tax rate | 18.1% | - | 24.6% | 19.9% | 20.3% | - | 25.9% | 46.6% | 26.0% | - |
| Return on assets | 2.6% | - | 4.2% | 3.6% | 4.3% | - | 5.0% | 1.4% | 4.5% | - |
| Return on equity | 3.6% | - | 6.1% | 5.1% | 6.3% | - | 7.7% | 2.2% | 7.4% | - |
| Return on invested capital | 2.9% | - | 5.0% | 4.2% | 5.1% | - | 6.0% | 1.6% | 5.6% | - |
| Liquidity | ||||||||||
| Current ratio | 3.58 | 3.60 | 3.75 | 3.84 | 3.67 | 3.31 | 3.24 | 3.13 | 3.11 | 2.75 |
| Quick ratio | 3.56 | 3.58 | 3.72 | 3.80 | 3.63 | 3.27 | 3.20 | 3.09 | 3.07 | 2.72 |
| Cash ratio | 2.71 | 2.98 | 2.90 | 3.03 | 2.79 | 2.59 | 2.40 | 2.16 | 2.16 | 1.90 |
| Leverage | ||||||||||
| Debt / Equity | 0.15 | 0.17 | 0.18 | 0.20 | 0.22 | 0.25 | 0.28 | 0.32 | 0.34 | 0.38 |
| Debt / Assets | 0.11 | 0.11 | 0.12 | 0.14 | 0.15 | 0.16 | 0.18 | 0.20 | 0.21 | 0.22 |
| Debt / EBITDA | 3.72 | - | - | - | 2.81 | - | - | - | 3.35 | - |
| Interest coverage | 11.5x | - | 18.1x | 13.2x | 14.7x | - | 14.2x | 4.8x | 11.5x | - |
| Equity multiplier | 1.40 | 1.46 | 1.45 | 1.43 | 1.46 | 1.52 | 1.56 | 1.59 | 1.64 | 1.74 |
| Liabilities / Assets | 0.28 | 0.32 | 0.31 | 0.30 | 0.32 | 0.34 | 0.36 | 0.37 | 0.39 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.20 | 0.18 | 0.18 | - | 0.20 | 0.20 | 0.18 | - |
| Inventory turnover | 8.43 | - | 8.67 | 6.25 | 5.01 | - | 6.19 | 5.70 | 4.69 | - |
| Days sales outstanding | 183d | - | 153d | 169d | 209d | - | 160d | 176d | 188d | - |
| Days inventory outstanding | 43d | - | 42d | 58d | 73d | - | 59d | 64d | 78d | - |
| Days payable outstanding | 235d | - | 161d | 271d | 199d | - | 90d | 258d | 201d | - |
| Cash conversion cycle | -8d | - | 34d | -43d | 83d | - | 129d | -18d | 65d | - |
| Valuation | ||||||||||
| P / E | 50.9x | - | 31.7x | 46.5x | 42.6x | - | 50.6x | 150.8x | 50.1x | - |
| P / B | 1.8x | - | 1.9x | 2.4x | 2.7x | - | 3.9x | 3.2x | 3.8x | - |
| P / S | 7.6x | - | 6.8x | 9.2x | 10.5x | - | 12.5x | 10.0x | 12.5x | - |
| EV / EBITDA | 32.1x | - | - | - | 28.6x | - | - | - | 34.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 16.6% | - | 28.7% | 16.0% | 19.5% | - | 16.1% | 28.8% | 29.8% | - |
| Revenue CAGR (3y) | 21.8% | - | 26.9% | 23.3% | 29.4% | - | 32.1% | 32.8% | 98.3% | - |
| Revenue CAGR (5y) | 61.1% | - | 39.3% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 11.9% | - | 25.5% | 15.4% | 20.1% | - | 11.9% | 28.8% | 29.3% | - |
| Operating income growth (YoY) | -33.7% | - | 6.1% | 125.6% | 8.1% | - | -4.3% | -54.5% | 28.7% | - |
| Net income growth (YoY) | -28.7% | - | 10.4% | 243.2% | 18.9% | - | 19.8% | -66.2% | 30.0% | - |
| EPS growth (YoY) | -29.5% | - | 10.1% | 240.0% | 16.4% | - | 25.4% | -64.3% | 39.6% | - |
| EPS CAGR (3y) | 4.6% | - | -15.5% | 20.4% | 30.6% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 8.7% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 26.3% | 32.0% | 39.9% | 43.5% | 39.8% | 41.1% | 24.0% | 11.0% | 16.3% | 15.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$868.45M totalRare Neurological Diseases Segment$868.45M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Harmony Biosciences Holdings against the 5 most active filers in the same SIC group.